Investing Club
Share
CNBC Investing Club

Jim Cramer explains why he's bullish on Eli Lilly despite its Alzheimer's drug's regulatory obstacle

Cramer explained why the regulatory obstacle facing Eli Lilly's Alzheimer's drug doesn't change his opinion of the stock.
07:10
Mon, Jan 23 20237:11 PM EST